Loading
After six cycles of chemotherapy, staying on a low-dose tablet and the antibody delayed the cancer's return without spoiling quality of life.
CAIRO3 randomised 558 patients whose metastatic colorectal cancer was stable or responding after six three-weekly cycles of capecitabine, oxaliplatin and bevacizumab to maintenance capecitabine with bevacizumab or to observation, with the induction regimen reintroduced at first progression in both arms. The primary endpoint, progression-free survival 2, was 11.7 months with maintenance against 8.5 months with observation (hazard ratio 0.67, 95% CI 0.56 to 0.81), and quality of life was not compromised. CAIRO3 is why induction followed by maintenance, rather than continuous full-dose chemotherapy, is the shape of first-line treatment in metastatic colorectal cancer.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares VEGF / VEGFR, Anti-angiogenic therapy, Bevacizumab, Cytotoxic chemotherapy.
Shares CAPOX (capecitabine, oxaliplatin), Anti-angiogenic therapy, Bevacizumab, Colorectal cancer.
Shares VEGF / VEGFR, Anti-angiogenic therapy, Bevacizumab, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Anti-angiogenic therapy, Bevacizumab, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Anti-angiogenic therapy, Bevacizumab, Capecitabine.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Anti-angiogenic therapy, Bevacizumab, Colorectal cancer.